Regeneron Pharmaceuticals (REGN) Cash from Financing Activities (2009 - 2026)

Regeneron Pharmaceuticals has reported Cash from Financing Activities for 18 years, with the latest figure at -$802.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 26.35% year-over-year to -$802.2 million; the trailing twelve-month figure through Mar 2026 stood at -$3.4 billion (down 2.75% YoY), and the FY2025 full-year result was -$3.7 billion, down 68.84% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$802.2 million, down from -$780.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $64.7 million in Q1 2022, with the low at -$1.1 billion in Q4 2024.
• Average Cash from Financing Activities over 5 years is -$559.8 million, with a median of -$614.2 million recorded in 2023.
• Year-over-year, Cash from Financing Activities soared 117.66% in 2022 and sank 2412.53% in 2025.
• Tracing REGN's Cash from Financing Activities over 5 years: stood at -$247.6 million in 2022, then plunged by 80.17% to -$446.1 million in 2023, then plunged by 154.54% to -$1.1 billion in 2024, then jumped by 31.3% to -$780.1 million in 2025, then retreated by 2.83% to -$802.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$802.2 million (Q1 2026), -$780.1 million (Q4 2025), and -$717.9 million (Q3 2025), per Business Quant data.

Peer Comparison